Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: brevagen  phenogen  sciences  breast  cancer  patient  risk  women  health  mammograms  healthcare  multivu  58399  cvs  pharmacy  als  fundraising  campaign  research  support  ata  healthcare  multivu  44466  amber  riley  mean  stinks  secret  clinical  strength  deodorant  facebook  bullying  glee  pacer  consumer  multivu  50863  antimicrobial  copper  clinical  trial  hospitals  healthcare  acquired  infections  icu  patients  health  multivu  61120  sutter  neuroscience  institute  autism  treatment  stem  cells  research  study  health  multivu  57707  health  healthcare  sentara  leigh  hospital  treatment  cdifficile  cure  infection  copper  oxide  multivu  7955751  avon  anew  clinical  pro  line  eraser  treatment  anti  aging  wrinkles  skincare  multivu  52897  copper  development  greence  sustainability  arizona  health  sciences  innovative  construction  architects  multivu  61608  researchers  dietary  banned  stimulants  unapproved  pills  recall  medical  multivu  8216951  bayer  advanced  aspirin  tablets  healthcare  pain  relief  pro-release  gesics  cardiovascular  consumer  multivu  50414  bc  veritor  system  test  reader  flu  consumer  multivu  53615  best  clinical  research  institutes  in  bangalore 
Search // clinical
Results 1-12 of 101 for ' clinical ' (0 seconds)
Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun’s innovative “first-in-class” anti-heart failure drug, Neucardin™. To view Multimedia News Release, go to http://www.multivu.com/mnr/61677-zensun-completes-clinical-trials-of-neucardin-treatment-of-heart-failure
Added: 3962 days ago by MultiVuVideos
Runtime: 3m28s | Views: 894 | Comments: 1
Not yet rated
 

 

 

A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma. A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia. “We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.” To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Categories // People and Blog 
Added: 4333 days ago by MultiVuVideo
Runtime: 4m41s | Views: 4476 | Comments: 0
Not yet rated
 

 

 

Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) (“DelMar Pharma” or “DelMar”) discusses new clinical research and treatments in development for glioblastoma, the most common and severe form of brain cancer. Less than one out of three patients will survive two years after their diagnosis. DelMar is a cancer-focused company developing new therapies for patients with little to no treatment options. To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7037951-delmar-pharmaceuticals-glioblastoma-brain-tumor-awareness-month
Categories // Science and Technology 
Added: 3619 days ago by MultiVuVideos
Runtime: 6m10s | Views: 1005 | Comments: 1
Not yet rated
 

 

 

Today, WebMD released In Their Own Words: Moving Beyond Migraine with Robin Roberts, a new five-part video series that sheds light on the debilitating nature of migraine and the impact it has on all aspects of a sufferer’s personal and professional life. To learn more about treatments and the individuals featured in In Their Own Words: Moving Beyond Migraine with Robin Roberts, visit: to www.webmd.com/insidemigraines. Moving Beyond Migraine follows the lives of Jennifer, a public school administrator who has lived with intense migraine headaches for over 20 years; Kate, a 20-year-old college student with debilitating migraines that have run in her family for generations; Melanie, whose intense migraine condition has altered the dynamics of her nine year marriage; and Lynn, who after suffering from migraine for 50 years, shares how a clinical trial for a new treatment called CGRP targeted therapy is finally providing her with some relief. To view the multimedia release go to: https://www.multivu.com/players/English/7579759-robin-roberts-moving-beyond-migraine/
Categories // Miscellaneous 
Added: 2467 days ago by MultiVuVideos
Runtime: 1m4s | Views: 679 | Comments: 1
Not yet rated
 

 

 

University Hospitals (UH) Case Medical Center has announced a $250 million initiative that promises to dramatically change how drugs will advance from discovery in the laboratories to commercialization, resulting in greater access to advanced treatments and cures for patients. The first-of-its-kind initiative, named The Harrington Project for Discovery & Development, is powered by a $50 million gift – the largest donation in the health system’s history – from the Harrington family, recognized entrepreneurs and philanthropists in Cleveland. To view Multimedia News Release, go to http://www.multivu.com/mnr/54909-university-hospitals-uh-harrington-discovery-institute-development-project
Categories // News and Politics 
Added: 4411 days ago by MultiVuVideos
Runtime: 2m53s | Views: 5500 | Comments: 0
Not yet rated
 

 

 

Online Registration Guidline ACRI is specialized in providing Clinical Research Courses like Pg Diploma in clinical CDM and SAS course with guarantee internship in leading CRO’S & 100% Placement. Reach us at: Avigna Clinical Research Institute:- No.33,3rd Floor,15th Cross, 2nd Phase,J.P.Nagar,100ft Ring Road, Bangalore-560078 080-26588910 / 91-9741600499 http://www.acriindia.com info@acriindia.com
Tags // best  clinical  research  institutes 
Categories // Business 
Added: 3745 days ago by Avigna
Runtime: 2m38s | Views: 803 | Comments: 0
Not yet rated
 

 

 

Invuity, Inc. (NASDAQ:IVTY), an advanced medical technology company, announced today the launch of its Hidden ScarTM Surgery program designed to certify surgeons and establish Centers of Excellence at major cancer centers and hospitals across the country. This innovative program will train surgeons on advanced minimally invasive and minimal access surgical approaches that deliver optimal clinical and aesthetic outcomes for patients. As part of the company’s broader women’s health initiative, Invuity is hosting a Hidden Scar Breast Cancer Surgery training course in advance of the American College of Surgeons (ACS) Clinical Congress. Invuity aims to transform the surgical treatment of breast cancer with this advanced surgical approach for nipple sparing mastectomies and lumpectomies (breast conserving surgery). Hidden Scar Breast Cancer Surgery expands surgical options for patients, offering superior cosmetic outcomes that can improve their psychological and emotional recovery and enhance quality of life after surgery.1 With growing demand for less invasive alternatives to breast cancer surgery, surgeons need to operate through smaller incisions with limited fields of vision. Invuity’s illumination technology allows surgeons to access and visualize the entire breast cavity through discrete incision locations, enabling surgeons to safely and effectively treat breast cancer while preserving the natural shape of the breast and thereby minimizing and hiding the scars. To view the multimedia release go to: http://www.multivu.com/players/English/7644051-invuity-hidden-scar-breast-cancer-surgery-program/
Categories // Miscellaneous 
Added: 3101 days ago by MultiVuVideos
Runtime: 3m30s | Views: 793 | Comments: 1
Not yet rated
 

 

 

After nearly eight years of careful planning, guests from across Illinois gathered today in Lake Forest to celebrate the ceremonial opening of the new Northwestern Medicine Lake Forest Hospital, which will officially open on March 3, 2018. The new state-of-the-art hospital, which broke ground in 2014, will provide patients convenient access to world-class physicians with seamless access to Northwestern Memorial Hospital, Illinois’s premier academic medical center when needed. The new Lake Forest Hospital will offer cutting-edge treatments and innovative clinical trials within a world class health system. To view the multimedia release go to: https://www.multivu.com/players/English/8213351-new-northwestern-medicine-lake-forest-hospital/
Categories // Miscellaneous 
Added: 2235 days ago by MultiVuVideos
Runtime: 1m6s | Views: 618 | Comments: 2
Not yet rated
 

 

 

Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its presence at the American Association for Clinical Chemistry (AACC) 2016 Clinical Lab Expo today by featuring several next-generation diagnostic testing platforms and a new virtual reality experience that gives attendees an “under the hood” look at a lab of the future and an innovative concept Roche calls the “Roche connected lab.” The virtual reality theater will enable attendees to view samples moving through a virtual lab equipped with various configurations of Roche automation, chemistry/immunoassay platforms and molecular diagnostics systems, as well as connections to third-party platforms. The actual Roche systems that are part of the connected lab concept will also be on display in the booth. To view the multimedia release go to: http://www.multivu.com/players/English/7889151-roche-aacc-2016/
Categories // Miscellaneous 
Added: 2795 days ago by MultiVuVideos
Runtime: 3m16s | Views: 679 | Comments: 0
Not yet rated
 

 

 

Texas Oncology (http://www.texasoncology.com) is one of the nation’s leading cancer treatment networks, offering experienced physicians, advanced technologies, clinical research, and leading-edge treatments to patients in the fight against cancer. With more than 300 physicians providing care at more than 100 sites of service throughout communities in Texas, New Mexico, and Oklahoma, Texas Oncology brings the power and resources of a world-class network to bear for cancer patients and their families every day. Celebrating its 25-year anniversary in 2011, Texas Oncology treats more Texans with cancer than any other provider in the state. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/texas-oncology/46947/
Added: 4874 days ago by MultiVuVideos
Runtime: 3m17s | Views: 6944 | Comments: 0
Not yet rated
 

 

 

Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Light Study, a long-term research study of Contrave® (naltrexone SR/bupropion SR), a new, investigational drug being evaluated for weight loss, has begun enrolling patients at clinical sites throughout the United States. The Light Study is designed to assess the cardiovascular health outcomes of Contrave. Nearly 93 million Americans are affected by obesity, and that number is predicted to increase to 120 million Americans within the next five years. More than one-third of adults in the United States are affected by obesity. Obesity increases the risk of heart disease, type 2 diabetes, some types of cancer, sleep apnea, and a variety of other conditions. Medical research suggests that losing just five percent of your body weight can significantly improve your health and reduce the risk of complications from type 2 diabetes and heart disease. To view Multimedia News Release, go to http://www.multivu.com/mnr/56480-lightstudy
Categories // Science and Technology 
Added: 4313 days ago by MultiVuVideos
Runtime: 4m3s | Views: 5053 | Comments: 0
Not yet rated
 

 

 

St. Jude Children’s Research Hospital, www.stjude.org, announced today the appointment of James R. Downing, M.D., as its new CEO, effective July 15, 2014. Downing most recently has served as the Deputy Director, Executive Vice President and Scientific Director of the hospital, which is leading the way the world understands, treats and defeats pediatric cancer and other catastrophic diseases. Downing’s primary focus immediately upon assuming the CEO office will be to oversee a new era of clinical, research and infrastructure expansion throughout the St. Jude global network. He succeeds Dr. William E. Evans, who is retiring from the position after 10 years and returning full time to his long-standing pharmacogenomics research program at St. Jude. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256651-st-jude-children-s-research-hospital-new-era-of-expansion-and-growth/
Categories // News and Politics 
Added: 3564 days ago by MultiVuVideos
Runtime: 2m50s | Views: 976 | Comments: 1
Not yet rated
 

 

 

Page 1 of 9  |  Go to page    Next» LAST»»



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2024 ClipMoon.com. All rights reserved.